Skip to content
iNOVA4Health - Advancing Precision Medicine
Menu
About Us
Mission
Collaborations
Partners
Management Board
Scientific Advisory Board
Careers
Contacts
Infrastructure
BioPilot Plant
GMP Analytical Services
GenIbet
NOVA-CRU
NIMSB Technology Platforms
Thematic Lines
TL1: Neurological and Vision Disorders
TL2: Cardio-Metabolic Disorders
TL3: Cancer
Research Groups
RG 1: Cell Bioprocesses for Advanced Therapies
RG 2: Molecular Biomarkers and Diagnosis
RG 3: Process Engineering for Biopharmaceuticals
RG 4: Protein Structure and Function in Biomedicine
RG 5: Health Function of Natural Bioactive Molecules
RG 6: Retinal Ageing and Disease
RG 7: Neuro-Inflammation
RG 8: Stroke and Neuroprotection
RG 9: Neurophysiology and Degeneration
RG10: Cardio-Vascular Diseases
RG11: Reno-Vascular Diseases
RG12: Diobesity
RG13: Musculoskeletal Immune-Regulation
RG14: Cell Metabolism and Cancer
RG15: Hepatobiliary and Pancreatic Cancer
RG16: Familial and Individual Cancer Risk
RG17: From Tumour Biology to Cancer Therapies
Highlights
Intranet
Search form
Search
IPO Lisboa: new branding, same values
13/02/2019
http://www.ipolisboa.min-saude.pt/
